Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Jaap Jan Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the use of early CD4+ T-cell reconstitution as a predictor of outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).